We are live on ! Find out more
LABP

Landos Biopharma, Inc. Common Stock
LABP

Delisted

LABP was delisted on the 23rd of May, 2024.

Back to rankings

16 hedge funds and large institutions have $34.9M invested in Landos Biopharma, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

525% more capital invested

Capital invested by funds: $5.58M → $34.9M (+$29.3M)

60% more funds holding

Funds holding: 10 → 16 (+6)

Holders
16
Holders Change
+6
Holders Change %
+60%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DAM
Deltec Asset Management
New York
+$332K
2
VF
Virtu Financial
New York
+$96.4K
3
BMCM
Black Maple Capital Management
Wisconsin
+$69K
4
PCM
PenderFund Capital Management
British Columbia, Canada
+$61.7K
5
Renaissance Technologies
Renaissance Technologies
New York
+$50.6K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$154
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$31.9M – – –
DAM
2
Deltec Asset Management
New York
$1.07M +$332K +50,000 New
Renaissance Technologies
3
Renaissance Technologies
New York
$406K +$50.6K +7,630 +68%
Macquarie Group
4
Macquarie Group
Australia
$316K – – –
VF
5
Virtu Financial
New York
$313K +$96.4K +14,537 New
Geode Capital Management
6
Geode Capital Management
Massachusetts
$271K – – –
PCM
7
PenderFund Capital Management
British Columbia, Canada
$271K +$61.7K +9,300 New
BMCM
8
Black Maple Capital Management
Wisconsin
$223K +$69K +10,405 New
UBS Group
9
UBS Group
Switzerland
$87.7K +$26.8K +4,042 +9,624%
TRCT
10
Tower Research Capital (TRC)
New York
$19.2K +$5.94K +896 New
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$2K – – –
JP Morgan Chase
12
JP Morgan Chase
New York
$1.27K – – –
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$1K +$405 +61 New
Morgan Stanley
14
Morgan Stanley
New York
$279 +$86 +13 New
CPG
15
Cornerstone Planning Group
New Jersey
$267 – – –
Wells Fargo
16
Wells Fargo
California
$215 – – –
BlackRock
17
BlackRock
New York
– -$154 -42 Closed

LABP Hedge Fund Activity: Q1 2024 in Review

16 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q1 2024, worth a combined $34.9M — up 525% from $5.58M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new LABP positions and 1 closed out — a net gain of 6 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Deltec Asset Management, opening a new position worth an estimated $332K. The largest seller was BlackRock, exiting entirely with an estimated $154 sold.

  • 16 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q1 2024, up from 10 in Q4 2023.
  • Funds reported $34.9M of Landos Biopharma, Inc. Common Stock stock for Q1 2024, up 525% quarter-over-quarter.
  • 7 funds opened new Landos Biopharma, Inc. Common Stock positions in Q1 2024 and 1 closed out, a net change of +6 holders.
  • The largest Landos Biopharma, Inc. Common Stock buyer in Q1 2024 was Deltec Asset Management, an estimated $332K added.
  • The largest Landos Biopharma, Inc. Common Stock seller in Q1 2024 was BlackRock, an estimated $154 sold.

Based on aggregated 13F filings for Q1 2024.